**American Journal of Biomedicine and Pharmacy**
https://biojournals.us/index.php/AJBP
**ISSN: 2997-7177**

# Chemical and Clinical Analysis of Blood Plasma Components and their Role in the Early Detection of Pathological Disorders

**Fatimah Abdul Razzak Mageed**
University of Karbala College of Education for pure Science Department of biology

**Mohammed Adel Hadi**
University of Diyala College of Science Department of Chemistry

**Zainab Kamal Kadem Jumaa**
University of Technology college of Applied Sciences Applied chemistry

**Afnan Sabah Mohammed Koba**
College of science University of Kufa Department of Pathological Analysis

**Received:** 2025, 15, Oct
**Accepted:** 2025, 21, Nov
**Published:** 2025, 10, Dec



**Annotation:** Blood plasma is an important diagnostic medium for a variety of pathological disorders, and it has the potential for enabling early-stage disease detection due to its distinct component profile. The present work aims to analyze and summarize the various chemical and clinical components present within blood plasma toward the goal of early-stage disease detection. Existing works have reported on the substantial plasma component profile but suffer from a mostly qualitative discussion of candidate markers. There is still an opportunity to deliver a more quantitative review specifically focused on the analysis of plasma components and on those relevant to early-stage detection of diseases as diverse as cardiovascular and renal disorders, diabetes, and infection.

Early detection of pathological disorders is a prime objective of clinical analyses. Blood is the most widely studied biofluid in clinical diagnostics due to its ease of access and rich information. Blood plasma is of particular interest because it is the liquid portion of blood following complete coagulation and contains a

chemical composition reflecting a larger area of the body than other sample types such as serum or whole blood. Because disease typically influences the chemistry of the body, changes in blood plasma composition have the potential to serve as diagnostic biomarkers for clinical pathologies.

## 1. Introduction

Plasma constitutes over 55% of the total blood volume and plays a critical role in sustaining life by effectively transporting cells, essential nutrients, and vital signalling molecules throughout the body. The various components of plasma can serve as significant diagnostic indicators of pathological changes and the presence of diseases. Large-scale studies have demonstrated that employing multiscale analytical approaches to probe plasma components can effectively track disease onset, progression, and the effects of treatments, which makes blood plasma a highly valuable medium for biomarkers that drive the early diagnosis of diverse health issues, including vascular, neurological, psychiatric, metabolic, and tumoral disorders (Zhu, 2024). Ultrasensitive and reliable analysis techniques have proven instrumental in capturing the rich information content of plasma that is dictated by individual health status and lifestyle choices across different spectra, including proteins, metabolites, lipids, or ions. This comprehensive analysis enables better understanding and monitoring of health conditions, thereby enhancing the potential for timely interventions and more personalized medical care. [1] [2][3]

## 2. Overview of Blood Plasma Composition

Blood plasma is a liquid component of blood that transports blood cells, nutrients, proteins, hormones, waste products, and other solutes throughout the circulatory system. Blood plasma proteins are categorized into three classes [1]. Plasma proteins are categorized into three classes: abundant proteins such as albumin and globulins, protein markers associated with pathological conditions, and signalling proteins for tissue communication, including cytokines and hormones. Blood plasma contains more than 700–1000 metabolites of low molecular weight, reflecting metabolic activity and the physiological status of an organism. In addition, blood plasma contains lipids, inorganic elements, and gases. Each plasma component has a reference range, the value outside of which may indicate a pathological stage. The composition of blood plasma is influenced by many physiological factors, such as age, sex, diet, time of specimen collection, and exercise, and thus the overall process of biomarker discovery and validation is extremely complex [4].

## 3. Analytical Techniques in Plasma Analysis

Blood plasma reflects a complex interplay of molecular species produced by various organs and tissues, constituting a rich analytical medium for clinical diagnostics [4]. Plasma samples contain an extensive repertoire of proteins, metabolites, lipids, and other bioactive molecules that maintain homeostatic functions. Early detection of pathophysiological states is expected to lead to better management of diseases and potentially change their course. Lesion-specific markers are appealing for biomarker discovery because they indicate the occurrence of an organ-based incident. Proteins and metabolites have been the two most widely studied classes of plasma molecules for early disease detection. Following the basic research that surfaced potential candidate markers—troponins for cardiac infarction, prostate-specific antigen for prostate cancer, microalbumin for renal dysfunction, glucose for diabetes, lactate for sepsis, bilirubin for liver impairment, and catecholamines for stress—international multi-national cohort studies were organized as part of large-scale validation programs.

The analysis of low-molecular-weight plasma components classifies into small-scale untargeted studies, mass-spectrometry-based metabonome research aiming at larger biohazard biomarker discovery, and target-specific rutinous metabolic profiling, performed either with small or UPLC systems. Lipid molecules have received increasing interest in these schemes for their roles in systemic detoxication, inflammatory, and metabolic signaling; mopnserous lipid mediators also have potential to be biohazard biomarkers for bioactury security. Lipids account for a higher proportion than proteins in the blood and their stable, semi-quantitative follow-up monitoring does not show perturbation from punctures, prudent for remaining as much liquid admission for forthcoming analyses. The species and particles of lipids, including fatty acids, glycerolipids, sphingolipids, sterols, at the molecular level as well as nanometer-scaled lipoproteins, are exammined and disclosed potential ranges needed for associating dyslipidemic pathologies. [5][6][7]

## 4. Proteomic and Metabolomic Markers in Early Disease Detection

Proteins represent the principal biomarkers currently supported by clinical guidelines and employed in routine diagnostic tests based on commercial kits for blood plasma and serum. The availability of immunoassay platforms has enabled the clinical use of protein analytes detectable in the low ng/mL range [4]. Examples of protein markers incorporated in monitoring systems at the clinical scale include, among others, cardiac troponin for myocardial infarction, thyroglobulin for thyroid cancer recurrence, and C-reactive protein for infection or inflammation. Furthermore, peripheral blood plasma proteins also convey significant information in the characterisation of disease status. For example, protein abundance ratios such as AFP-L3 for hepatocellular carcinoma or specific modifications such as glycosylation of HbA1c for diabetes lend themselves to disease monitoring and individual risk thresholds. By contrast, other blood components have proven to be of limited support for the purpose of early disease detection: circulating tissue cells, although potentially informative for monitoring purposes, present considerable challenges for the early diagnosis of de novo tumours; circulating DNA willingly encapsulates individual risk information and aids prenatal non-invasive diagnosis; and circulating RNA carries personal information regarding an individual’s baseline but lacks robust links to individual health status. Finally, small-molecule metabolites play a central role in biological processes and significantly vary under pathological conditions. However, the overall value of metabolites in the realm of diagnostics is limited in comparison to proteomics and genomics when devoted to interrogate the capacity of blood for supporting early disease detection [8]. There exists a large and significant medical need for blood-based tests that would render possible the timely detection of diseases and the regular monitoring of general health status. For the above-mentioned reasons, blood plasma or serum is considered as a strong candidate to provide biomarkers for the early detection of diseases. Furthermore, comprehensive standardised protocols for sample collection, stabilisation, processing and analysis are required to favour the large-scale discovery and clinical validation of highly reproducible biomarkers.

## 5. Lipidomics and Lipoprotein Profiling for Pathology Risk Assessment

Blood lipids and lipoproteins are major components of plasma, which contains various lipids (triglycerides, cholesterol, fatty acids, phospholipids, and apolipoproteins), and the circulating lipid pattern (lipidomic), that reflect metabolic derangements involved in diseases such as atherosclerosis. Lipids are important for growth, reproduction, energy storage, signalling, and membrane structure, and other essential cellular functions; thus lipid composition, levels, and stepwise mechanisms are essential. Moreover, lipidomic analysis helps understanding of the underlying mechanisms by precisely delving into the many cellular events at the lipid class, subclass, molecular species, and position levels, and lipids constitute a multitude of molecular species, which are not covered by conventional analysis [9].

Despite a low proportion of circulating phospholipids, the composition of different lipid species of phospholipid particles mirrors that of their parent particles, and changes in lipid composition

upon dilution or during a disease state of circulation can even offer describable insight into the progression of that disease state [10]. There is a relationship between lipocalin and metabolic signalling, where lipocalins regulate fatty acid metabolism, and lipocalins cooperate with other proteins (such as several apolipoproteins and albumin) to form additional particles that carry selective lipid species, further modifying the unfolding lipid signal. Early stages of metabolic syndrome generally describe patients with lipidomic particle signatures that still largely reflect the normolipidomic state, although systemic signals from adipose tissue and lipocalins circulating in the plasma gradually dictate a profound remodelling of predominant lipoprotein classes transported in blood.

## 6. Plasma Proteins as Biomarkers for Cardiovascular and Renal Diseases

Patient blood plasma comprises highly dynamic proteins. Diagnosis of cardiovascular diseases using plasma has proven easier than with other organs and more reliable than analysis of the circulating metabolites and lipoproteins. For instance, cardiac troponins are well-validated biomarkers for diagnosis of myocardial infarction and non-ST-elevation myocardial infarction. B-type natriuretic peptides and N-terminal pro B-type natriuretic peptides indicate acute heart failure. In chronic kidney diseases, low plasma albumin and high microalbumin levels denote deterioration and early-stage disorders, respectively. Reliable research underpins these data-driven observations and enables classification of the various plasma proteins and their clinical implications [11].

## 7. Coagulation Factors and Hemostatic Markers in Early Pathology

Ageing and exposure to cardiovascular risk factors contribute to arterial stiffening and changes in the quantitative and qualitative composition of atherogenic blood lipids, both of which are involved in the initiation and progression of cardiovascular disease (CVD). During its course, CVD may evolve from a clinically unapparent stage to an overt condition, e.g. from enhanced risk (presence of significant risk factors but no clinical manifestations) to preclinical (asymptomatic) and finally to clinical (symptomatic) stages [12]. Most cardiovascular events, when they occur, are attributed to instability of plaque lesions. Arterial stiffness and blood atherogenic lipids remain as key evaluators of preclinical phases of CVD. Atherogenic blood lipids can be identified through quantitative determination of convincing and well-researched surrogate markers. In atherogenic blood, a high ratio of polyunsaturated to saturated triglycerides and a predominance of small-sized low-density lipoprotein (LDL) particles and their surrogates characterise the luggage of lipids associated with atherogenic blood.

## 8. Immunoglobulins and Immune-Related Plasma Constituents in Disease Onset

Besides immunoglobulin G (IgG) and A (IgA), which participate in autoimmune processes and allergic reactions [13], four immunoglobulin classes (IgM, IgD, and IgE) and some IgG subclasses (IgG1, IgG2, IgG3, and IgG4) exhibit differential synthesis patterns and are directly involved in the onset and early progression of various diseases. Autoantibodies (abs) against multiple self-antigens—such as dsDNA, chromatin, histones, cardiolipin, phosphatidylserine, smooth muscle, myeloperoxidase, and glutamic acid decarboxylase—often precede the development of diverse autoimmune disorders. These self-directed IgA and IgG abs have become standard criteria for the diagnosis of systemic lupus erythematosus, scleroderma, Sjögren’s syndrome, and other autoimmune diseases. Additional examples include anti-plaque abs for Alzheimer’s disease [14] , anti-SARS-CoV-2 abs for COVID-19 [15] , and abs against increasing numbers of other autoantigens for other major public health problems.

The complement system comprises more than 30 soluble and membrane-associated proteins that cooperate in innate and adaptive immunity. Its components and activation fragments serve as key signalling molecules in the signaling pathways of several immune cells. Although dysregulation occurs at later disease stages, complement levels can become abnormally elevated or reduced in the early phases of human and animal infections and autoimmune disorders.

## 9. Clinical Translation: From Biomarker Discovery to Diagnostic Tools

The clinical validation of candidate biomarkers follows a sequence of steps that inform their potential as diagnostic tools: initial discovery is conducted in well-defined cohorts, determining the pool of analytes associated with disease; a wider pool of candidate markers is then identified through non-targeted but quantitative analysis combined with analytical profiles obtained from publicly available databases. At this point, concentration pathways, statistical associations, and analyses of biological pathways in common candidate markers solidify a list of analytes. External validation in cohorts independent of both the discovery and preclinical settings is then necessary to establish clinical readiness.

Biomarkers used for early diagnostics should fulfill certain criteria: they must allow detection before disease onset, permit quantitative analyses feasible with large cohorts, clearly associate with biological pathways, and enable an understanding of their mechanistic role. In the validation-testing phase, the regulatory potential of the proposed markers is examined and classified as either in vitro diagnostic medical device or laboratory-based. These routes differ markedly in requirements and labor, with submissions to competent authorities taking significantly longer than requests to circular ecdb1dab36-0993-473e-8ab0-e755add048a1mies or local health ministries. Following the prevalidation testing, work focuses on the development of a QTof- or QqQ-based analysis method that spans a significant set of the proposed preclinical markers to determine clinical relevance in biological fluids other than plasma, notably urine, bile, or synovial liquid.

The regulatory process involves completion of required documentation, collection of preclinical data supplied by CROs, finalisation of the analysis method, and preparation of the assay. For in vitro diagnostic medical devices, preclinical data must validate the QTof/QqQ analysis and demonstrate stability during storage or processing. The quality of preclinical data influences the solution selected; laboratory-based marking, requiring only proof of analytical detection per path, has progressed faster than much of the still-pending QTof- and QqQ-combined regulatory documentation [4].

The development of confirmatory, non-targeted, and large-scale multi-omic truism marker sets remains the centre of attention; green fluorescent protein, fluorescein, and 2,7-dichlorofluorescein continue to be pursued as alternative detection-conjugated-marker candidates. These projects keep generating, duplicating, and shifting other compounds both preclinically and clinically, enabling participation along multiple lines that strengthen pro-activity [8].

## 10. Statistical and Methodological Considerations in Plasma Analysis

Pre-analytical variables, such as the timing and method of blood collection and subsequent handling procedures, have a significant influence on the composition and observed variability of plasma proteomes. The choice of blood collection tube plays an important role in sample preservation and integrity. The collection of blood aliquots followed by appropriate storage at low temperature (preferably −80 °C) is essential for both proteomic biomarker discovery but also protein quantification across multiple time points to model long-range dynamic changes, such as those related to circadian rhythms. The implementation of globally recognized biomarker validation standards, such as those established by the “Biomarkers Definitions Working Group” [4] , is critical, as is the establishment of open-submission repositories that could potentially be integrated into future Plasma and ROCIS-Metabolomics collaboration activities.

Both the assessment and rapid feedback of data quality and the assessment of systematic deviations introduced prior to analysis are paramount in maintaining statistical power throughout, yet there remain considerable discrepancies in the computational and statistical analyses of the remaining datasets in open-access repositories throughout the biomarker community. Plasma remains one of the most challenging tissues to study due to the high

concentration ranges of the proteins present, large dynamic ranges, and the presence of large interfering molecules such as lipids. Consequently, the accompanying concentration ranges of many biomarker candidates of interest remain considerably diminished throughout acquisition and within useable quantification limits.

## 11. Ethical, Regulatory, and Practical Implications of Plasma-Based Diagnostics

The ethical implications of accessing data on plasma components for early disease detection are critical for refining the regulatory framework of omics-based medical techniques applicable to health and illness monitoring of the population [16]. The metabolites, lipids, and proteins present in plasma equilibrate with bodily components to reflect physiological processes. Monitoring selected features enables tracking of additional metabolic and molecular derangements preceding the onset of overt illness, thereby serving as a possible preventive strategy. However, there is growing evidence that plasma proteomes contain robust markers allowing re-identification of individuals. Depending on the context, detailed knowledge of such plasma signatures may provoke undesirable consequences, including discrimination.

The ethical and regulatory considerations accompanying fresh opportunities for homogeneous, standardized, and comprehensive plasma analysis must be elucidated. The three arenas of ethical, regulatory, and practical implications are tightly intertwined and not easy to disentangle. Access to data on certain plasma compounds enables non-invasive assessment of disease presence, activity, and progression [4]. However, concerns about effective consent to research and health monitoring studies become pertinent, especially when involving unwilling subjects or non-consensual access to stored samples from deserted sites. الطريقة المفضلة والتقنية //---------- ---------- - behalf of regulatory bodies overseeing official monitoring studies and custom-made analyses of eHealth governing bodies will be proposed to ensure the ratio of ethically and socially acceptable investigation remains safeguarded.

## 12. Conclusions

The composition of blood plasma is a multifaceted representation of an individual’s physiological state. The analysis of blood plasma systems for biomarker discovery has become of particular interest owing to their involvement in various pathologies. Several plasma components have been associated and correlated with clinical manifestations accompanying minor diseases and early stages of severe diseases. Examples of such components are low molecular weight proteins, low-density lipoproteins, hemostatic components, immunoglobulins, and several others. However, the clinical applicability of these numerous candidate markers has not gathered momentum, as collaborative research amongst different clinical laboratories still remains critical for clinical implementation.

## References:

1. P. E Geyer, L. M Holdt, D. Teupser, and M. Mann, "Revisiting biomarker discovery by plasma proteomics," 2017. ncbi.nlm.nih.gov
2. D. S. Smirnov, N. J. Ashton, K. Blennow, H. Zetterberg, et al., "Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change," *Acta …*, 2022. springer.com
3. A. Bodaghi, N. Fattahi, and A. Ramazani, "Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases," Heliyon, 2023. cell.com
4. Y. Zhu, "Plasma/Serum Proteomics based on Mass Spectrometry," 2024. ncbi.nlm.nih.gov
5. K. R. Feingold, "Introduction to lipids and lipoproteins," Endotext [internet], 2024. nih.gov

6. R. Cai, J. Ren, M. Guo, T. Wei, Y. Liu, C. Xie, et al., "Dynamic intracellular exchange of nanomaterials' protein corona perturbs proteostasis and remodels cell metabolism," *Proceedings of the National Academy of Sciences*, 2022. pnas.org
7. N. Chander, G. Basha, M. H. Y. Cheng, et al., "Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues," *Therapy Methods &…*, 2023. cell.com
8. M. Ono, M. Kamita, Y. Murakoshi, J. Matsubara et al., "Biomarker Discovery of Pancreatic and Gastrointestinal Cancer by 2DICAL: 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry," 2012. ncbi.nlm.nih.gov
9. K. Ekroos, M. Jänis, K. Tarasov, R. Hurme et al., "Lipidomics: A Tool for Studies of Atherosclerosis," 2010. ncbi.nlm.nih.gov
10. A. Lamaziere, C. Wolf, and P. J. Quinn, "Perturbations of Lipid Metabolism Indexed by Lipidomic Biomarkers," 2012. ncbi.nlm.nih.gov
11. C. M. Ghantous, L. Kamareddine, R. Farhat, F. A. Zouein et al., "Advances in Cardiovascular Biomarker Discovery," 2020. ncbi.nlm.nih.gov
12. B. B. Sempasa, "Clotting analysis of blood samples from intensive care unit patients.," 2009. [PDF]
13. I. Awan, "Autoantigens Underlying IgG4 Related Disease," 2017. [PDF]
14. G. Z. Garyfallou, O. Ketebu, S. Şahin, E. B. Mukaetova-Ladinska et al., "Electrochemical Detection of Plasma Immunoglobulin as a Biomarker for Alzheimer’s Disease," 2017. ncbi.nlm.nih.gov
15. X. Liu, Y. Cao, H. Fu, J. Wei et al., "Proteomics Analysis of Serum from COVID-19 Patients," 2021. ncbi.nlm.nih.gov
16. P. E. Geyer, S. Porsdam Mann, P. V. Treit, and M. Mann, "Plasma Proteomes Can Be Reidentifiable and Potentially Contain Personally Sensitive and Incidental Findings," 2021. ncbi.nlm.nih.gov